The role of selective estrogen receptor modulators in the treatment of schizophrenia.
BACKGROUND
Gender differences in schizophrenia have been recognized for a long time and it has been widely accepted that sex steroid hormones, especially estradiol, are strongly attributed to this fact. Two hypotheses regarding estradiol action in psychoses gained special research attention - the estrogen protection hypothesis and hypoestrogenism hypothesis. A growing number of studies have shown benefits in augmenting antipsychotic treatment with estrogens or selective estrogen receptor modulators (SERM).


METHODS
This review is focused on the role of selective estrogen receptor modulators in the treatment of schizophrenic patients. In order to achieve this result PubMed was searched using the following terms: schizophrenia, raloxifene, humans. We reviewed only randomized, placebo-controlled studies.


RESULTS
Raloxifene, a selective estrogen receptor modulator was identified as useful to improve negative, positive, and general psychopathological symptoms, and also cognitive functions. All reviewed studies indicated improvement in at least one studied domain. Augmentation with raloxifene was found to be a beneficial treatment strategy for chronic schizophrenia both in female and male patients, however potential side effects (a small increase in the risk of venous thromboembolism and endometrial cancer) should be carefully considered.


CONCLUSIONS
SERMs could be an effective augmentation strategy in the treatment of both men women with schizophrenia, although further research efforts are needed to study potential long-term side effects.
Department of Psychiatry and Psychotherapy, Independent Public Clinical Hospital No. 7 of Silesian Medical University, Ziołowa 45-47, Katowice, Poland, agn.bratek@gmail.com.
Agnieszka
A
Bratek
Krzysztof
K
Krysta
Karolina
K
Drzyzga
Justyna
J
Barańska
Krzysztof
K
Kucia